New Zealand-based firm Mesynthes is on course to break into the international wound care sector by the end of this year, the company's CEO has told Clinica. The US FDA is expected to approve a 510(k) application for the company's lead product, an extracellular matrix (ECM) designed to ...
Please Login to read the full article.
